illimaquinone has been researched along with Retinal Neovascularization in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YS; Chung, H; Jang, H; Kang, W; Kim, JH; Lim, D; Liu, KH; Na, M; O, Y; Oh, S; Park, S; Shin, S; Son, Y; Song, GY; Song, IS | 1 |
1 other study(ies) available for illimaquinone and Retinal Neovascularization
| Article | Year |
|---|---|
Ilimaquinone inhibits neovascular age-related macular degeneration through modulation of Wnt/β-catenin and p53 pathways.
Topics: Angiogenesis Inhibitors; Animals; beta Catenin; Cell Line; Choroidal Neovascularization; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Macular Degeneration; Male; Mice, Inbred C57BL; Quinones; Rabbits; Retinal Neovascularization; Retinal Vessels; Sesquiterpenes; Tumor Suppressor Protein p53; Wnt Signaling Pathway | 2020 |